Stock market investors may be holding back dollars from public biopharmaceutical firms as macroeconomic issues and other factors severely impact company valuations, but venture capital investment has kept up a robust pace in 2022, as evidenced by the 29 June announcement that ARCH Venture Partners raised $2.975bn for ARCH Venture Fund XII.
ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund
Fund XII Brings In New And Existing Investors
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
